- Active not recruitingPHASE3
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
This study looks at new drug combinations (fianlimab with cemiplimab) versus a standard drug (pembrolizumab) to see if they can stop melanoma from coming back after surgery. It's for people at high risk of their melanoma returning.
For: MelanomaUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MOIO_Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with locally advanced or metastatic cancer in response after 6 months of standard IO
This study compares standard immunotherapy with a reduced dose for people whose cancer responded well after 6 months. It looks at how long they stay well and their quality of life. The aim is to see if a lower dose can be just as effective.
For: Only patients with oncologic locally advanced or metastatic tumour (lung cancer · renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination) · head and neck cancerFrance - RecruitingPHASE1, PHASE2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
This study is testing a new drug, ubamatamab, alone or with cemiplimab, for recurrent ovarian or endometrial cancer. It aims to see how safe it is, how it works in the body, and if it can help treat these cancers.
For: Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal CancerUnited States · Australia · Belgium - RecruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Germany - Active not recruitingPHASE3
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
This study looks at a new drug, cemiplimab, for people who have had surgery and radiotherapy for a serious form of skin cancer (squamous cell carcinoma). We want to see if cemiplimab can stop the cancer from coming back.
For: Cutaneous Squamous Cell CarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE1, PHASE2
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is looking at new combinations of immunotherapy drugs for people with advanced lung cancer. It combines an existing drug, Cemiplimab, with one of three new drugs (S095018, S095024, or S095029) to see which combination is safe and works best.
For: Non-small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - Active not recruitingPHASE3
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
This study is comparing two drug combinations for advanced melanoma skin cancer: fianlimab plus cemiplimab, and pembrolizumab. It aims to see which is more effective, what side effects occur, and how they affect adults and teenagers.
For: MelanomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
This study is looking at a new drug combination for lung cancer that can be removed by surgery. It aims to see if adding Fianlimab to standard treatment (Cemiplimab and chemotherapy) works better and is safe for adults with certain types of non-small cell lung cancer.
For: Resectable Non-small Cell Lung CancerUnited States · Australia · Chile - Active not recruitingPHASE1, PHASE2
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)
This study is testing a new combination of two medicines, Tuvusertib and Cemiplimab, for people with a specific type of lung cancer (non-squamous NSCLC). It's for those whose cancer has grown despite previous treatments, including immunotherapy and chemotherapy.
For: Non-Small Cell Lung CancerUnited States · Belgium · France - Active not recruitingPHASE2, PHASE3
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study looks at a new drug, fianlimab, combined with cemiplimab, for advanced lung cancer. It aims to see if this combination works better than cemiplimab alone, studying side effects and how treatments affect quality of life.
For: Advanced Non-Small Cell Lung CancerUnited States · Australia · Canada - Active not recruitingPHASE2
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
This study looks at a new combination of drugs, fianlimab and cemiplimab, for melanoma skin cancer. We want to see if this combination works better and is safe compared to cemiplimab alone for people with certain stages of melanoma that can be removed by surgery.
For: MelanomaUnited States · Australia · Austria - RecruitingPHASE3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
This study aims to see if a special ultrasound device, Exablate, can help standard cancer medicines work better for people with lung cancer that has spread to the brain. Researchers will compare this new approach to standard care alone.
For: Brain Tumor · Non Small Cell Lung CancerUnited States · Canada · South Korea - RecruitingPHASE2
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
This study looks at a new drug called Cemiplimab for advanced skin cancer (basal cell carcinoma) that hasn't been treated before with certain other drugs. We want to see how well it works and if it's safe as a first treatment.
For: Basal Cell Carcinoma (BCC) · First Line TreatmentGermany - RecruitingPHASE2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat early-stage lung cancer. We want to see if adding an extra treatment to cemiplimab and chemotherapy works better before surgery. It's for adults whose lung cancer can be removed by an operation.
For: Non-Small Cell Lung CancerUnited States · Brazil · France - RecruitingPHASE1, PHASE2
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
This study looks at a new drug, Marlotamig, by itself and with other treatments for advanced cancers. We want to see if it's safe, how well it works, and find the best dose to help shrink tumours.
For: Advanced Solid TumorsUnited States · France · Israel - Active not recruitingPHASE1, PHASE2
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
This study is looking at a new medicine called HST-1011, sometimes with another medicine called cemiplimab, for adults with advanced solid cancers. It's for people whose cancer hasn't responded to previous treatments or has come back after them.
For: Solid Tumor, Adult · Relapsed Cancer · Refractory CancerUnited States · Canada · Spain - Recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
This study looks at how a medicine called cemiplimab (Libtayo®) works for adults with advanced non-small cell lung cancer in everyday healthcare. Researchers want to understand its benefits and safety in real-world use.
For: Non-small Cell Lung CancerAustria · France · Germany